Alzamend Neuro's Losses Mount Amid R&D Surge, Going Concern Doubts

Ticker: ALZN · Form: 10-Q · Filed: Dec 9, 2025 · CIK: 1677077

Sentiment: bearish

Topics: Biotechnology, Clinical Stage, Alzheimer's Disease, Going Concern, R&D Expenses, Net Loss, Reverse Stock Split

TL;DR

**ALZN is burning cash fast on R&D, and with a 'going concern' warning, expect more dilution or a desperate scramble for funds; stay away.**

AI Summary

Alzamend Neuro, Inc. (ALZN) reported a net loss of $1.0 million for the three months ended October 31, 2025, a decrease from $1.4 million in the same period of 2024. For the six months ended October 31, 2025, the net loss was $3.7 million, an increase from $2.3 million in the prior year. Research and development expenses significantly increased to $1.9 million for the six months ended October 31, 2025, up from $517,659 in 2024, reflecting intensified focus on its AL001 and ALZN002 drug candidates for Alzheimer's and other neurological disorders. General and administrative expenses remained relatively stable at $1.78 million for the six-month period. The company's cash position improved to $4.4 million as of October 31, 2025, from $3.9 million at April 30, 2025, primarily due to $4.0 million in net proceeds from preferred stock issuance. Despite this, ALZN continues to operate at a loss, with an accumulated deficit of $62.2 million, and management explicitly states substantial doubt about its ability to continue as a going concern without additional capital. Two reverse stock splits were executed: a one-for-ten split on July 16, 2024, and a one-for-nine split on May 12, 2025, impacting share count and per-share metrics.

Why It Matters

Alzamend Neuro's increasing R&D spend, while crucial for drug development, is rapidly depleting cash and exacerbating net losses, raising significant red flags for investors. The explicit 'going concern' warning in the filing signals a high probability of further dilutive equity financing or debt, directly impacting existing shareholders. For employees and customers, the company's long-term viability hinges on successful clinical trials and securing substantial funding, placing future prospects in a precarious position. In the competitive biopharmaceutical landscape, ALZN's struggle to fund its pipeline for Alzheimer's and other neurological disorders highlights the immense capital requirements and inherent risks of clinical-stage drug development.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about our ability to continue as a going concern' and has an accumulated deficit of $62.2 million as of October 31, 2025. Cash used in operating activities for the six months ended October 31, 2025, was $3.5 million, indicating a rapid cash burn relative to its $4.4 million cash balance.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ALZN stock due to the explicit going concern warning and significant accumulated deficit. Current shareholders should prepare for potential further dilution as the company seeks additional financing to fund its operations and R&D programs.

Financial Highlights

debt To Equity
0.16
revenue
N/A
operating Margin
N/A
total Assets
$5.1 million
total Debt
$0.7 million
net Income
-$3.7 million
eps
-$1.33
gross Margin
N/A
cash Position
$4.4 million
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were Alzamend Neuro's net losses for the recent periods?

Alzamend Neuro reported a net loss of $1.0 million for the three months ended October 31, 2025, and a net loss of $3.7 million for the six months ended October 31, 2025. This compares to net losses of $1.4 million and $2.3 million for the respective periods in 2024.

How much cash does Alzamend Neuro have and what is its burn rate?

As of October 31, 2025, Alzamend Neuro had $4.4 million in cash. For the six months ended October 31, 2025, the company used $3.5 million in cash for operating activities, indicating a significant burn rate.

What is the significance of the 'going concern' disclosure for Alzamend Neuro?

The 'going concern' disclosure means that management expects to continue incurring losses and needs to raise additional capital to fund operations for the next twelve months. This creates substantial doubt about Alzamend Neuro's ability to continue operating without further financing, posing a high risk to investors.

What are Alzamend Neuro's primary drug candidates?

Alzamend Neuro's primary drug candidates are AL001, an ionic cocrystal technology for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD, and ALZN002, a cell-based therapeutic vaccine for Alzheimer's. Both are licensed from the University of South Florida Research Foundation, Inc.

How have Alzamend Neuro's research and development expenses changed?

Research and development expenses for Alzamend Neuro significantly increased to $1.9 million for the six months ended October 31, 2025, compared to $517,659 for the same period in 2024. This reflects increased investment in its drug pipeline.

What impact did the reverse stock splits have on Alzamend Neuro's shares?

Alzamend Neuro executed two reverse stock splits: a one-for-ten split effective July 16, 2024, and a one-for-nine split effective May 12, 2025. These splits reduced the number of outstanding common shares, impacting per-share metrics like net loss per common share.

How does Alzamend Neuro plan to address its funding needs?

Alzamend Neuro plans to seek additional funding through public equity, private equity, and debt financings. The company acknowledges that the terms of any additional financing may adversely affect the holdings or rights of its stockholders.

What is Alzamend Neuro's accumulated deficit?

As of October 31, 2025, Alzamend Neuro's accumulated deficit stood at $62.2 million, reflecting the cumulative net losses incurred since its inception.

Has Alzamend Neuro generated any product revenue to date?

No, Alzamend Neuro has not generated any product revenue to date. The company is a clinical-stage biopharmaceutical company focused on research and development.

What are the potential consequences if Alzamend Neuro cannot obtain additional funding?

If Alzamend Neuro is unable to obtain additional funding, it could be required to delay, reduce, or eliminate its research and development programs and planned clinical trials. This would adversely affect the company's business operations and its ability to bring treatments to market.

Risk Factors

Industry Context

Alzamend operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on treatments for neurological disorders like Alzheimer's. This field is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. Success hinges on groundbreaking research, substantial funding, and navigating complex approval processes.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Alzamend is subject to stringent regulations from bodies like the FDA. The development and approval process for its drug candidates (AL001 and ALZN002) are lengthy and costly, with a high risk of failure. Any adverse findings in clinical trials or regulatory reviews could severely impact the company's prospects.

What Investors Should Do

  1. Monitor R&D progress and clinical trial results closely.
  2. Assess cash runway and future financing needs.
  3. Understand the impact of reverse stock splits on share count and valuation.

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, with Alzamend having a deficit of $62.2 million as of October 31, 2025.)
Going concern
An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Management has expressed substantial doubt about Alzamend's ability to continue as a going concern without additional funding, highlighting significant financial instability.)
Reverse stock split
A corporate action to reduce the number of outstanding shares of stock, usually to increase the share price. (Alzamend has executed two reverse stock splits (1-for-10 in July 2024 and 1-for-9 in May 2025), significantly impacting share count and per-share calculations.)
Additional paid-in capital
The amount of money a company receives from selling stock above its par value. (Represents a significant source of funding for Alzamend, totaling $66.6 million as of October 31, 2025, primarily from equity issuances.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Alzamend Neuro's net loss widened from $2.3 million to $3.7 million, primarily driven by a substantial increase in research and development expenses to $1.9 million. While total operating expenses rose, general and administrative costs remained relatively stable. The company's cash position saw a modest improvement, bolstered by preferred stock issuance, but the overall financial picture remains challenging with a significant accumulated deficit and ongoing operational losses.

Filing Stats: 4,581 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2025-12-09 16:30:59

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Balance Sheets 3 Condensed Statements of Operations 4 Condensed Statements of Stockholders' Equity 5 Condensed Statements of Cash Flows 9 Notes to Condensed Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 31

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Alzamend Neuro, Inc. Condensed Balance Sheets October 31, 2025 April 30, 2025 (Unaudited) (Audited) ASSETS CURRENT ASSETS Cash $ 4,449,433 $ 3,948,658 Prepaid expenses and other current assets 272,015 228,719 TOTAL CURRENT ASSETS 4,721,448 4,177,377 Property, plant and equipment, net 370,236 425,606 TOTAL ASSETS $ 5,091,684 $ 4,602,983 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 717,488 $ 634,761 TOTAL LIABILITIES, ALL CURRENT 717,488 634,761 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Series B Convertible Preferred Stock; nil 0 designated and nil 0 issued and outstanding as of October 31, 2025 and 6,000 shares designated, $ 1,000 issued and outstanding as of April 30, 2025 - - Common stock, $ 0.0001 par value: 300,000,000 shares authorized; 3,801,604 and 778,733 issued and outstanding as of October 31, 2025 and April 30, 2025, respectively 380 78 Additional paid-in capital 66,612,519 62,503,405 Accumulated deficit ( 62,238,703 ) ( 58,535,261 ) TOTAL STOCKHOLDERS' EQUITY 4,374,196 3,968,222 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 5,091,684 $ 4,602,983 The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Alzamend Neuro, Inc. Condensed Statements of Operations (Unaudited) For the Three Months Ended October 31, For the Six Months Ended October 31, 2025 2024 2025 2024 OPERATING EXPENSES Research and development $ 176,283 $ 311,088 $ 1,917,150 $ 517,659 General and administrative 821,826 1,046,980 1,781,160 1,802,814 Total operating expenses 998,109 1,358,068 3,698,310 2,320,473 Loss from operations ( 998,109 ) ( 1,358,068 ) ( 3,698,310 ) ( 2,320,473 ) OTHER EXPENSE, NET Interest expense ( 2,649 ) ( 3,495 ) ( 5,132 ) ( 15,501 ) Total other expense, net ( 2,649 ) ( 3,49

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing